| abstract |
A novel mono-sialo ganglioside derivative substantially identical chemically and physically with a product prepared by (a) concentration of an aqueous solution of a mono-sialo ganglioside and calcium ions under sub-atmospheric pressure at 40 DEG -80 DEG C. for 18-240 hours, (b) adjustment of the pH to 2-3, followed by dialysis, and (c) evaporation of the aqueous solvent. The novel ganglioside is believed to be a new physical form of the known ganglioside GM1 and shows activity against bacteria, viruses, protozoal, fungi and tumors. It has previously been suggested that gangliosides in general may be useful in the treatment of neurological disorders but not that they affect the activity of phagocytes. |